2017-2022 Global and Japan RNAi for Therapeutic Market Analysis Report

Published: Aug, 2017 | Pages: 127 | Publisher: JP Research
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

The global RNAi for Therapeutic market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%.

This report, with focus on top players in the global and Japan, studies the RNAi for Therapeutic market's development status and future trend in the global and Japan. It splits RNAi for Therapeutic market by type and by applications to fully and deeply research and reveal market profile and prospect.

The major players include
    Alnylam Pharmaceuticals (USA)
    Arbutus Biopharma (Tekmira) (Canada)
    Arrowhead Research (USA)
    Dicerna Pharmaceuticals (USA)
    Mirna Therapeutics (USA)
    Quark Pharmaceuticals (Israel)
    RXi Pharmaceuticals (USA)
    Silence Therapeutics (Germany)
    Benitec Biopharma (Australia)
    miRagen Therapeutics (USA)
    Sylentis (Spain)
    Gradalis (USA)
    Sirnaomics (USA)
    Silenseed (Israel)
    Arcturus Therapeutics (USA)
    Arcturus Therapeutics (USA)
    Ariz Biopharma (USA)
    GeneCopoeia (USA)
    Ascletis Pharmaceuticals (USA)
    Celsion Corporation (USA)
    Astellas Pharma (USA)
    AstraZeneca (UK)
    BioSpring (Vietnam)
    Calando Pharmaceuticals (USA)
    Celgene (USA)
    Bayer Heathcare (USA)
    Biogazelle (Belgium)
    CombiMatrix (USA)
    Creative Animodel (USA)
    Ensysce Biosciences (USA)

Geographically, this report splits the Global market into the following regions:
    Asia Pacific
        Japan
            Tokyo
            Yokohama
            Osaka
            Nagoya
            Others
        China
        Korea
        India
        Others
    Europe
        France
        Germany
        United Kingdom
        Italy
        Russia
        Others
    North America
        United States
        Canada
    Latin America
        Brazil
        Mexico
        Others
    Southeast Asia
        Singapore
        Malaysia
        Vietnam
        Myanmar
        Thailand
        Indonesia
        Philippines
        Others
    Middle East & Africa
        Saudi Arabia
        Iran
        UAE
        Turkey
        Israel
        Egypt
        South Africa
        Others

On the basis of product, the RNAi for Therapeutic market is primarily split into
By Technology
    siRNA
    miRNA
    shRNA
By Molecular Form
    Single Chain
    Double Chain

Key Applications
    Cancer
    Cardiovascular
    HBV
    Other

 Table of Contents

2017-2022 Global and Japan RNAi for Therapeutic Market Analysis Report
1 RNAi for Therapeutic Overview
    1.1 Product Overview and Scope of RNAi for Therapeutic
    1.2 Global and Japan RNAi for Therapeutic Market by Applications/End Users
        1.2.1 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
            1.2.1.1 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share by Applications (2012-2017)
            1.2.1.2 Japan RNAi for Therapeutic Sales Growth Rate (%) by Applications (2012-2017)
            1.2.1.3 Market Drivers and Opportunities
        1.2.2 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
        1.2.3 Global RNAi for Therapeutic Sales by Application (2012-2017)
            1.2.3.1 Global RNAi for Therapeutic Sales (K Pcs) and Market Share by Applications (2012-2017)
            1.2.3.2 Global RNAi for Therapeutic Sales Growth Rate (%) by Applications (2012-2017)
            1.2.3.3 Market Drivers and Opportunities
        1.2.4 Global RNAi for Therapeutic Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
        1.2.5 Cancer
        1.2.6 Cardiovascular
        1.2.7 HBV
        1.2.8 Other
    1.3 Global and Japan Market Size (Sales and Revenue) of RNAi for Therapeutic (2012-2017)
        1.3.1 Japan Market Size (Sales and Revenue) of RNAi for Therapeutic (2012-2017)
            1.3.1.1 Japan RNAi for Therapeutic Sales (K Pcs) and Growth Rate (%) (2012-2017)
            1.3.1.2 Japan RNAi for Therapeutic Revenue (Million USD) and Growth Rate (2012-2017)
        1.3.2 Global Market Size (Sales and Revenue) of RNAi for Therapeutic (2012-2017)
            1.3.2.1 Global RNAi for Therapeutic Sales (K Pcs) and Growth Rate (%) (2012-2017)
            1.3.2.2 Global RNAi for Therapeutic Revenue (Million USD) and Growth Rate (2012-2017)
    1.4 Global and Japan Classification of RNAi for Therapeutic by Technology
        1.4.1 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share by Technology (2012-2017)
        1.4.2 Global RNAi for Therapeutic Sales (K Pcs) and Market Share by Technology (2012-2017)
        1.4.3 Japan RNAi for Therapeutic Revenue (Million USD) and Market Share by Technology (2012-2017)
        1.4.4 Global RNAi for Therapeutic Revenue (Million USD) and Market Share by Technology (2012-2017)
        1.4.5 Japan RNAi for Therapeutic Price (USD/Pcs) by Technology (2012-2017)
        1.4.6 Global RNAi for Therapeutic Price (USD/Pcs) by Technology (2012-2017)
        1.4.7 Japan RNAi for Therapeutic Sales Growth Rate (%) by Technology (2012-2017)
        1.4.8 Global RNAi for Therapeutic Sales Growth Rate (%) by Technology (2012-2017)
        1.4.9 siRNA
        1.4.10 miRNA
        1.4.11 shRNA
    1.5 Global and Japan Classification of RNAi for Therapeutic by Molecular Form
        1.5.1 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share by Molecular Form (2012-2017)
        1.5.2 Global RNAi for Therapeutic Sales (K Pcs) and Market Share by Molecular Form (2012-2017)
        1.5.3 Japan RNAi for Therapeutic Revenue (Million USD) and Market Share by Molecular Form (2012-2017)
        1.5.4 Global RNAi for Therapeutic Revenue (Million USD) and Market Share by Molecular Form (2012-2017)
        1.5.5 Japan RNAi for Therapeutic Price (USD/Pcs) by Molecular Form (2012-2017)
        1.5.6 Global RNAi for Therapeutic Price (USD/Pcs) by Molecular Form (2012-2017)
        1.5.7 Japan RNAi for Therapeutic Sales Growth Rate (%) by Molecular Form (2012-2017)
        1.5.8 Global RNAi for Therapeutic Sales Growth Rate (%) by Molecular Form (2012-2017)
        1.5.9 Single Chain
        1.5.10 Double Chain

2 Global and Japan RNAi for Therapeutic Market Competition by Players/Manufacturers
    2.1 Japan RNAi for Therapeutic Market Competition by Players/Manufacturers
    2.1.1 Japan RNAi for Therapeutic Sales and Market Share of Key Players/Manufacturers (2012-2017)
    2.1.2 Japan RNAi for Therapeutic Revenue and Share by Players/Manufacturers (2012-2017)
    2.1.3 Japan RNAi for Therapeutic Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
    2.1.4 Japan RNAi for Therapeutic Market Competitive Situation and Trends
        2.1.4.1 Japan RNAi for Therapeutic Market Concentration Rate
        2.1.4.2 Japan RNAi for Therapeutic Market Share of Top 3 and Top 5 Players/Manufacturers
        2.1.4.3 Mergers & Acquisitions, Expansion in Japan Market
    2.1.5 Japan Players/Manufacturers RNAi for Therapeutic Manufacturing Base Distribution, Sales Area, Product Types
    2.2 Global RNAi for Therapeutic Market Competition by Players/Manufacturers
    2.2.1 Global RNAi for Therapeutic Sales and Market Share of Key Players/Manufacturers (2012-2017)
    2.2.2 Global RNAi for Therapeutic Revenue and Share by Players/Manufacturers (2012-2017)
    2.2.3 Global RNAi for Therapeutic Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
    2.2.4 Global RNAi for Therapeutic Market Competitive Situation and Trends
        2.2.4.1 Global RNAi for Therapeutic Market Concentration Rate
        2.2.4.2 Global RNAi for Therapeutic Market Share of Top 3 and Top 5 Players/Manufacturers
        2.2.4.3 Mergers & Acquisitions, Expansion in Global Market
    2.2.5 Global Players/Manufacturers RNAi for Therapeutic Manufacturing Base Distribution, Sales Area, Product Types

3 Global and Japan RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
    3.1 Asia Pacific RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
        3.1.1 Japan RNAi for Therapeutic Sales and Revenue  (2012-2017)
            3.1.1.1 Japan RNAi for Therapeutic Sales (K Pcs) and Market Share  (2012-2017)
            3.1.1.2 Japan RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.1.1.3 Japan RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.1.2 China RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.1.2.1 China RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.1.2.2 China RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.1.2.3 China RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.1.3 Korea RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.1.3.1 Korea RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.1.3.2 Korea RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.1.3.3 Korea RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.1.4 India RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.1.4.1 India RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.1.4.2 India RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.1.4.3 India RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.1.5 Others RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.1.5.1 Others RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.1.5.2 Others RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.1.5.3 Others RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
    3.2 Europe RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
        3.2.1 France RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.2.1.1 France RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.2.1.2 France RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.2.1.3 France RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.2.2 Germany RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.2.2.1 Germany RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.2.2.2 Germany RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.2.2.3 Germany RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.2.3 United Kingdom RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.2.3.1 United Kingdom RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.2.3.2 United Kingdom RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.2.3.3 United Kingdom RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.2.4 Italy RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.2.4.1 Italy RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.2.4.2 Italy RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.2.4.3 Italy RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.2.5 Russia RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.2.5.1 Russia RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.2.5.2 Russia RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.2.5.3 Russia RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.2.6 Others RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.2.6.1 Others RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.2.6.2 Others RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.2.6.3 Others RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
    3.3 North America RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
        3.3.1 United States RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.3.1.1 United States RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.3.1.2 United States RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.3.1.3 United States RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.3.2 Canada RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.3.2.1 Canada RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.3.2.2 Canada RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.3.2.3 Canada RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
    3.4 Latin America RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
        3.4.1 Brazil RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.4.1.1 Brazil RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.4.1.2 Brazil RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.4.1.3 Brazil RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.4.2 Mexico RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.4.2.1 Mexico RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.4.2.2 Mexico RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.4.2.3 Mexico RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.4.3 Others RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.4.3.1 Others RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.4.3.2 Others RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.4.3.3 Others RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
    3.5 Southeast Asia RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
        3.5.1 Singapore RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.5.1.1 Singapore RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.5.1.2 Singapore RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.5.1.3 Singapore RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.5.2 Malaysia RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.5.2.1 Malaysia RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.5.2.2 Malaysia RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.5.2.3 Malaysia RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.5.3 Vietnam RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.5.3.1 Vietnam RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.5.3.2 Vietnam RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.5.3.3 Vietnam RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.5.4 Myanmar RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.5.4.1 Myanmar RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.5.4.2 Myanmar RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.5.4.3 Myanmar RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.5.5 Thailand RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.5.5.1 Thailand RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.5.5.2 Thailand RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.5.5.3 Thailand RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.5.6 Indonesia RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.5.6.1 Indonesia RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.5.6.2 Indonesia RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.5.6.3 Indonesia RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.5.7 Philippines RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.5.7.1 Philippines RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.5.7.2 Philippines RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.5.7.3 Philippines RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.5.8 Others RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.5.8.1 Others RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.5.8.2 Others RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.5.8.3 Others RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
    3.6 Middle East & Africa RNAi for Therapeutic Sales and Revenue by Regions (2012-2017)
        3.6.1 Saudi Arabia RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.6.1.1 Saudi Arabia RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.6.1.2 Saudi Arabia RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.6.1.3 Saudi Arabia RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.6.2 Iran RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.6.2.1 Iran RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.6.2.2 Iran RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.6.2.3 Iran RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.6.3 UAE RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.6.3.1 UAE RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.6.3.2 UAE RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.6.3.3 UAE RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.6.4 Turkey RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.6.4.1 Turkey RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.6.4.2 Turkey RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.6.4.3 Turkey RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.6.5 Israel RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.6.5.1 Israel RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.6.5.2 Israel RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.6.5.3 Israel RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.6.6 Egypt RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.6.6.1 Egypt RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.6.6.2 Egypt RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.6.6.3 Egypt RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.6.7 South Africa RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.6.7.1 South Africa RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.6.7.2 South Africa RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.6.7.3 South Africa RNAi for Therapeutic Price (USD/Pcs)(2012-2017)
        3.6.8 Others RNAi for Therapeutic Sales and Revenue (2012-2017)
            3.6.8.1 Others RNAi for Therapeutic Sales (K Pcs) and Market Share (2012-2017)
            3.6.8.2 Others RNAi for Therapeutic Revenue (Million USD) and Market Share (2012-2017)
            3.6.8.3 Others RNAi for Therapeutic Price (USD/Pcs)(2012-2017)

4 Global and Japan RNAi for Therapeutic Players/Manufacturers Profiles and Sales Data
    4.1 Alnylam Pharmaceuticals (USA)
        4.1.1 Company Basic Information, Manufacturing Base and Competitors
        4.1.2 RNAi for Therapeutic Product Category, Application and Specification
            4.1.2.1 Product A
            4.1.2.2 Product B
        4.1.3 Alnylam Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.1.4 Main Business/Business Overview
    4.2 Arbutus Biopharma (Tekmira) (Canada)
        4.2.1 Company Basic Information, Manufacturing Base and Competitors
        4.2.2 RNAi for Therapeutic Product Category, Application and Specification
            4.2.2.1 Product A
            4.2.2.2 Product B
        4.2.3 Arbutus Biopharma (Tekmira) (Canada) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.2.4 Main Business/Business Overview
    4.3 Arrowhead Research (USA)
        4.3.1 Company Basic Information, Manufacturing Base and Competitors
        4.3.2 RNAi for Therapeutic Product Category, Application and Specification
            4.3.2.1 Product A
            4.3.2.2 Product B
        4.3.3 Arrowhead Research (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.3.4 Main Business/Business Overview
    4.4 Dicerna Pharmaceuticals (USA)
        4.4.1 Company Basic Information, Manufacturing Base and Competitors
        4.4.2 RNAi for Therapeutic Product Category, Application and Specification
            4.4.2.1 Product A
            4.4.2.2 Product B
        4.4.3 Dicerna Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.4.4 Main Business/Business Overview
    4.5 Mirna Therapeutics (USA)
        4.5.1 Company Basic Information, Manufacturing Base and Competitors
        4.5.2 RNAi for Therapeutic Product Category, Application and Specification
            4.5.2.1 Product A
            4.5.2.2 Product B
        4.5.3 Mirna Therapeutics (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.5.4 Main Business/Business Overview
    4.6 Quark Pharmaceuticals (Israel)
        4.6.1 Company Basic Information, Manufacturing Base and Competitors
        4.6.2 RNAi for Therapeutic Product Category, Application and Specification
            4.6.2.1 Product A
            4.6.2.2 Product B
        4.6.3 Quark Pharmaceuticals (Israel) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.6.4 Main Business/Business Overview
    4.7 RXi Pharmaceuticals (USA)
        4.7.1 Company Basic Information, Manufacturing Base and Competitors
        4.7.2 RNAi for Therapeutic Product Category, Application and Specification
            4.7.2.1 Product A
            4.7.2.2 Product B
        4.7.3 RXi Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.7.4 Main Business/Business Overview
    4.8 Silence Therapeutics (Germany)
        4.8.1 Company Basic Information, Manufacturing Base and Competitors
        4.8.2 RNAi for Therapeutic Product Category, Application and Specification
            4.8.2.1 Product A
            4.8.2.2 Product B
        4.8.3 Silence Therapeutics (Germany) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.8.4 Main Business/Business Overview
    4.9 Benitec Biopharma (Australia)
        4.9.1 Company Basic Information, Manufacturing Base and Competitors
        4.9.2 RNAi for Therapeutic Product Category, Application and Specification
            4.9.2.1 Product A
            4.9.2.2 Product B
        4.9.3 Benitec Biopharma (Australia) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.9.4 Main Business/Business Overview
    4.10 miRagen Therapeutics (USA)
        4.10.1 Company Basic Information, Manufacturing Base and Competitors
        4.10.2 RNAi for Therapeutic Product Category, Application and Specification
            4.10.2.1 Product A
            4.10.2.2 Product B
        4.10.3 miRagen Therapeutics (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        4.10.4 Main Business/Business Overview
    4.11 Sylentis (Spain)
    4.12 Gradalis (USA)
    4.13 Sirnaomics (USA)
    4.14 Silenseed (Israel)
    4.15 Arcturus Therapeutics (USA)
    4.16 Arcturus Therapeutics (USA)
    4.17 Ariz Biopharma (USA)
    4.18 GeneCopoeia (USA)
    4.19 Ascletis Pharmaceuticals (USA)
    4.20 Celsion Corporation (USA)
    4.21 Astellas Pharma (USA)
    4.22 AstraZeneca (UK)
    4.23 BioSpring (Vietnam)
    4.24 Calando Pharmaceuticals (USA)
    4.25 Celgene (USA)
    4.26 Bayer Heathcare (USA)
    4.27 Biogazelle (Belgium)
    4.28 CombiMatrix (USA)
    4.29 Creative Animodel (USA)
    4.30 Ensysce Biosciences (USA)

5 RNAi for Therapeutic Manufacturing Cost Analysis
    5.1 RNAi for Therapeutic Key Raw Materials Analysis
        5.1.1 Key Raw Materials
        5.1.2 Price Trend of Key Raw Materials
        5.1.3 Key Suppliers of Raw Materials
        5.1.4 Market Concentration Rate of Raw Materials
    5.2 Proportion of Manufacturing Cost Structure
        5.2.1 Raw Materials
        5.2.2 Labor Cost
        5.2.3 Manufacturing Expenses
    5.3 Manufacturing Process Analysis of RNAi for Therapeutic

6 Industrial Chain, Sourcing Strategy and Downstream Buyers
    6.1 RNAi for Therapeutic Industrial Chain Analysis
    6.2 Upstream Raw Materials Sourcing
    6.3 Raw Materials Sources of RNAi for Therapeutic Major Players/Manufacturers in 2016
    6.4 Downstream Buyers

7 Marketing Strategy Analysis, Distributors/Traders
    7.1 Marketing Channel
        7.1.1 Direct Marketing
        7.1.2 Indirect Marketing
        7.1.3 Marketing Channel Development Trend
    7.2 Market Positioning
        7.2.1 Pricing Strategy
        7.2.2 Brand Strategy
        7.2.3 Target Client
    7.3 Distributors/Traders List

8 Market Effect Factors Analysis
    8.1 Technology Progress/Risk
        8.1.1 Substitutes Threat
        8.1.2 Technology Progress in Related Industry
    8.2 Consumer Needs/Customer Preference Change
    8.3 Economic/Political Environmental Change

9 Global and Japan RNAi for Therapeutic Market Size (Sales and Revenue) Forecast (2017-2022)
    9.1 Global and Japan RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
    9.2 Global and Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Type (2017-2022)
        9.2.1 by Technology
        9.2.2 by Molecular Form
    9.3 Global and Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Application (2017-2022)
    9.4 Global and Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Regions (2017-2022)

10 Research Findings and Conclusion

11 Methodology and Data Source
    11.1 Methodology/Research Approach
        11.1.1 Research Programs/Design
        11.1.2 Market Size Estimation
        11.1.3 Market Breakdown and Data Triangulation
    11.2 Data Source
        11.2.1 Secondary Sources
        11.2.2 Primary Sources
    11.3 Disclaimer
    11.4 Author List

List of Tables and Figures

    Figure Product Picture of RNAi for Therapeutic
    Table Japan RNAi for Therapeutic Sales (Million Units) Comparison by Applications (2012-2017)
    Figure Japan Sales Market Share (%) of RNAi for Therapeutic by Applications in 2016
    Table Global RNAi for Therapeutic Sales (Million Units) Comparison by Applications (2012-2017)
    Figure Global Sales Market Share (%) of RNAi for Therapeutic by Applications in 2016
    Figure Cancer Examples
    Table Key Downstream Customer in Cancer
    Figure Cardiovascular Examples
    Table Key Downstream Customer in Cardiovascular
    Figure HBV Examples
    Table Key Downstream Customer in HBV
    Figure Other Examples
    Table Key Downstream Customer in Other
    Figure siRNA Product Picture
    Figure miRNA Product Picture
    Figure shRNA Product Picture
    Figure Single Chain Product Picture
    Figure Double Chain Product Picture
    Table Alnylam Pharmaceuticals (USA) Basic Information List
    Table Alnylam Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Alnylam Pharmaceuticals (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)
    Table Alnylam Pharmaceuticals (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)
    Figure Alnylam Pharmaceuticals (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)
    Table Arbutus Biopharma (Tekmira) (Canada) Basic Information List
    Table Arbutus Biopharma (Tekmira) (Canada) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Arbutus Biopharma (Tekmira) (Canada) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)
    Table Arbutus Biopharma (Tekmira) (Canada) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)
    Figure Arbutus Biopharma (Tekmira) (Canada) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)
    Table Arrowhead Research (USA) Basic Information List
    Table Arrowhead Research (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Arrowhead Research (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)
    Table Arrowhead Research (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)
    Figure Arrowhead Research (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)
    Table Dicerna Pharmaceuticals (USA) Basic Information List
    Table Dicerna Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Dicerna Pharmaceuticals (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)
    Table Dicerna Pharmaceuticals (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)
    Figure Dicerna Pharmaceuticals (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)
    Table Mirna Therapeutics (USA) Basic Information List
    Table Mirna Therapeutics (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Mirna Therapeutics (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)
    Table Mirna Therapeutics (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)
    Figure Mirna Therapeutics (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)
    Table Quark Pharmaceuticals (Israel) Basic Information List
    Table Quark Pharmaceuticals (Israel) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Quark Pharmaceuticals (Israel) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)
    Table Quark Pharmaceuticals (Israel) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)
    Figure Quark Pharmaceuticals (Israel) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)
    Table RXi Pharmaceuticals (USA) Basic Information List
    Table RXi Pharmaceuticals (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table RXi Pharmaceuticals (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)
    Table RXi Pharmaceuticals (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)
    Figure RXi Pharmaceuticals (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)
    Table Silence Therapeutics (Germany) Basic Information List
    Table Silence Therapeutics (Germany) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Silence Therapeutics (Germany) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)
    Table Silence Therapeutics (Germany) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)
    Figure Silence Therapeutics (Germany) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)
    Table Benitec Biopharma (Australia) Basic Information List
    Table Benitec Biopharma (Australia) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table Benitec Biopharma (Australia) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)
    Table Benitec Biopharma (Australia) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)
    Figure Benitec Biopharma (Australia) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)
    Table miRagen Therapeutics (USA) Basic Information List
    Table miRagen Therapeutics (USA) RNAi for Therapeutic Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
    Table miRagen Therapeutics (USA) RNAi for Therapeutic Sales Growth Rate (%)(2012-2017)
    Table miRagen Therapeutics (USA) RNAi for Therapeutic Sales Market Share (%) in Japan (2012-2017)
    Figure miRagen Therapeutics (USA) RNAi for Therapeutic Revenue Market Share (%) in Japan (2012-2017)
    Table Sylentis (Spain) Basic Information List
    Table Gradalis (USA) Basic Information List
    Table Sirnaomics (USA) Basic Information List
    Table Silenseed (Israel) Basic Information List
    Table Arcturus Therapeutics (USA) Basic Information List
    Table Arcturus Therapeutics (USA) Basic Information List
    Table Ariz Biopharma (USA) Basic Information List
    Table GeneCopoeia (USA) Basic Information List
    Table Ascletis Pharmaceuticals (USA) Basic Information List
    Table Celsion Corporation (USA) Basic Information List
    Table Astellas Pharma (USA) Basic Information List
    Table AstraZeneca (UK) Basic Information List
    Table BioSpring (Vietnam) Basic Information List
    Table Calando Pharmaceuticals (USA) Basic Information List
    Table Celgene (USA) Basic Information List
    Table Bayer Heathcare (USA) Basic Information List
    Table Biogazelle (Belgium) Basic Information List
    Table CombiMatrix (USA) Basic Information List
    Table Creative Animodel (USA) Basic Information List
    Table Ensysce Biosciences (USA) Basic Information List
    Table Production Base and Market Concentration Rate of Raw Material
    Figure Price Trend of Key Raw Materials
    Table Key Suppliers of Raw Materials
    Figure Manufacturing Cost Structure of RNAi for Therapeutic
    Figure Manufacturing Process Analysis of RNAi for Therapeutic
    Figure RNAi for Therapeutic Industrial Chain Analysis
    Table Raw Materials Sources of RNAi for Therapeutic Major Players/Manufacturers in 2016
    Table Major Buyers of RNAi for Therapeutic
    Table Distributors/Traders List
    Figure Japan RNAi for Therapeutic Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
    Figure Japan RNAi for Therapeutic Revenue (Million USD) and Growth Rate Forecast (2017-2022)
    Figure Japan RNAi for Therapeutic Price (USD/Pcs) Trend Forecast (2017-2022)
    Figure Global RNAi for Therapeutic Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
    Figure Global RNAi for Therapeutic Revenue (Million USD) and Growth Rate Forecast (2017-2022)
    Figure Global RNAi for Therapeutic Price (USD/Pcs) Trend Forecast (2017-2022)
    Table Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Type (2017-2022)
    Table Global RNAi for Therapeutic Sales (K Pcs) Forecast by Type (2017-2022)
    Figure Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Type (2017-2022)
    Figure Global RNAi for Therapeutic Sales (K Pcs) Forecast by Type (2017-2022)
    Figure Japan RNAi for Therapeutic Sales Volume Market Share Forecast by Type in 2017
    Figure Global RNAi for Therapeutic Sales Volume Market Share Forecast by Type in 2017
    Table Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Application (2017-2022)
    Figure Japan RNAi for Therapeutic Sales Volume Market Share Forecast by Application (2017-2022)
    Figure Japan RNAi for Therapeutic Sales Volume Market Share Forecast by Application in 2017
    Table Global RNAi for Therapeutic Sales (K Pcs) Forecast by Application (2017-2022)
    Figure Global RNAi for Therapeutic Sales Volume Market Share Forecast by Application (2017-2022)
    Figure Global RNAi for Therapeutic Sales Volume Market Share Forecast by Application in 2017
    Table Japan RNAi for Therapeutic Sales (K Pcs) Forecast by Regions (2017-2022)
    Table Japan RNAi for Therapeutic Sales Volume Share Forecast by Regions (2017-2022)
    Figure Japan RNAi for Therapeutic Sales Volume Share Forecast by Regions (2017-2022)
    Table Global RNAi for Therapeutic Sales (K Pcs) Forecast by Regions (2017-2022)
    Table Global RNAi for Therapeutic Sales Volume Share Forecast by Regions (2017-2022)
    Figure Global RNAi for Therapeutic Sales Volume Share Forecast by Regions (2017-2022)
    Table Research Programs/Design for This Report
    Figure Bottom-up and Top-down Approaches for This Report
    Figure Data Triangulation
    Table Key Data Information from Secondary Sources
    Table Key Data Information from Primary Sources